The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| VTGN | +34.75% | -81.9% | -28.95% | -100% |
| S&P | +12.57% | +87.93% | +13.44% | +420% |
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for anxiety, depression, and other central nervous system disorders. Its portfolio includes PH94B, a neuroactive nasal spray with potential to treat multiple anxiety disorders that the company is currently preparing for phase III clinical trial for social anxiety disorder, PH10, a neuroactive nasal spray that the company is planning for phase 2b development as a stand-alone treatment for major depressive disorder (MDD), and AV-101, which the company is developing for the treatment of MDD, suicidal ideation, neuropathic pain, levodopa-induced dyskinesia, and epilepsy. The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.24M | 190.5% |
| Gross Profit | $0.08M | 211.9% |
| Gross Margin | 30.74% | 110.5% |
| Market Cap | $58.32M | -38.0% |
| Market Cap / Employee | $1.02M | -55.4% |
| Employees | 57 | 39.0% |
| Net Income | -$15.10M | -40.6% |
| EBITDA | -$15.64M | -30.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $48.99M | -52.4% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.78M | -45.0% |
| Short Term Debt | $1.57M | 177.4% |
| Q4 2024 | YOY Change | |
|---|---|---|
| Return On Assets | -42.35% | -2.5% |
| Return On Invested Capital | -120.84% | -221.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$18.91M | -73.3% |
| Operating Free Cash Flow | -$18.85M | -73.4% |
| Metric | Q2 2024 | Q3 2024 | Q4 2024 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.82 | 0.78 | 0.86 | 0.70 | -39.68% |
| Price to Sales | 134.13 | 109.75 | 105.29 | 129.74 | -10.47% |
| Price to Tangible Book Value | 0.82 | 0.78 | 0.86 | 0.70 | -39.68% |
| Enterprise Value to EBITDA | -0.01 | 0.25 | -0.25 | -0.19 | -91.52% |
| Return on Equity | -46.5% | -59.5% | -61.5% | -46.3% | 3.89% |
| Total Debt | $1.99M | $1.79M | $1.71M | $2.36M | 11.13% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
